InvestorsHub Logo
Followers 9
Posts 2033
Boards Moderated 0
Alias Born 08/26/2010

Re: hutschi post# 193222

Friday, 10/10/2014 12:05:18 PM

Friday, October 10, 2014 12:05:18 PM

Post# of 345969
Not too favorable but has its merits.

Peregrine Pharmaceuticals' (NASDAQ:PPHM) lead drug bavituximab, a monoclonal antibody turned I-O, is in Phase III for NSCLC, but critics question improvements following lackluster and unreliable Phase II data and wonder why more robust statistical information is not provided
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News